drugset / Trial / NCT02205905
An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects
Phase 1
Completed
6 enrolled
AMAG Pharmaceuticals, Inc.
World Wide Clinical Trials Early Phase Services, LLC · collab
NaSingle-groupOpen-labelBasic science
Summary
This is an open-label, single-dose, non-randomized study in healthy male subjects to characterize the mass balance, metabolic disposition, and identification of the metabolites and general metabolic pathways following administration of a single dose of IV solution containing 200 mg of PER977 plus a tracer amount of 14C PER977 in health male subjects.
Timeline
- Start
- 2014-07
- Primary completion
- 2014-08
- Completion
- 2014-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ciraparantag | Small molecule | 200 mg | Intravenous |
Indications
No indication recorded.